ストックスクリーナーアプリを入手
34.74
3.45%
1.16
アフターアワーズ：
34.07
-0.67
-1.93%
前日終値:
$33.58
開ける：
$33.58
24時間の取引高:
2.11M
Relative Volume:
0.86
時価総額：
$4.34B
収益：
$1.12B
当期純損益:
$5.00M
株価収益率:
3,474.00
EPS:
0.01
ネットキャッシュフロー:
$-383.00M
1週間 パフォーマンス:
+5.43%
1か月 パフォーマンス:
-4.06%
6か月 パフォーマンス:
+102.68%
1年 パフォーマンス:
+189.02%
1日の値動き範囲:
$33.54
$34.94
1週間の範囲:
$32.66
$34.94
52週間の値動き範囲:
$7.62
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
名前
Indivior Pharmaceuticals Inc
セクター
電話
804-379-1090
住所
234 BATH ROAD, SLOUGH, BERKSHIRE
INDV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
34.74 | 4.20B | 1.12B | 5.00M | -383.00M | 0.01 |
|
ZTS
Zoetis Inc
|
124.96 | 54.61B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.91 | 52.47B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.42 | 46.18B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.53 | 36.87B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
476.78 | 20.38B | 3.08B | 1.24B | 1.07B | 25.61 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-22 | 再開されました | Jefferies | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-23 | 開始されました | Piper Sandler | Overweight |
| 2024-04-03 | 開始されました | Craig Hallum | Buy |
| 2023-07-13 | 開始されました | Northland Capital | Outperform |
すべてを表示
Indivior Pharmaceuticals Inc (INDV) 最新ニュース
Indivior completes redomiciliation from UK to US By Investing.com - Investing.com Nigeria
Aug PreEarnings: Is Indivior PLC vulnerable to short sellersQuarterly Market Review & Growth Focused Stock Reports - baoquankhu1.vn
Indivior announces completion of redomiciliation to U.S. - TipRanks
Indivior (INDV) Completes Move from UK to US, Listed on Nasdaq - GuruFocus
Indivior completes redomiciliation from UK to US - Investing.com
Indivior Announces Completion of Redomiciliation to the United States - GlobeNewswire
Indivior PLC: Can a Focused Addiction-Treatment Portfolio Power the Next Wave of Growth? - AD HOC NEWS
Is Indivior PLC forming higher highs and higher lowsJuly 2025 Macro Moves & Weekly Hot Stock Watchlists - mfd.ru
(INDV) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Indivior’s 2026 Revenue Guidance Tightens Expectations Might Change The Case For Investing In Indivior (INDV) - Yahoo Finance
Aug Selloffs: Can Indivior PLC stock outperform in a bear marketJuly 2025 Technicals & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Indivior PLC: Can a Focused Addiction-Treatment Specialist Win the Next Decade of Mental Health Phar - AD HOC NEWS
Grail and Indivior PLC come out on top in healthcare quant picks ahead of Q4 earnings - MSN
Market Wrap: Will WNEB outperform small cap indexes2025 Sector Review & Trade Opportunity Analysis - baoquankhu1.vn
Indivior (NASDAQ:INDV) Downgraded to "Hold" Rating by Zacks Research - MarketBeat
Indivior PLC: How a Specialist Addiction Franchise Is Quietly Rebuilding a Global Pharma Contender - AD HOC NEWS
Indivior (INDV) Price Target Increased by 13.21% to 43.71 - Nasdaq
Q1 Earnings Forecast for Indivior Issued By HC Wainwright - MarketBeat
Portfolio Update: Is now the right time to enter Indivior PLCJuly 2025 Chart Watch & Accurate Entry/Exit Alerts - baoquankhu1.vn
Indivior PLC (INDV) Stock Analysis: Exploring a 24% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Aug Setups: Does Indivior PLC stock trade at a discount to peersMarket Activity Summary & Safe Capital Growth Tips - Bộ Nội Vụ
Risks Report: Will Indivior PLC stock remain a Wall Street favorite2025 Technical Patterns & Free Real-Time Volume Trigger Notifications - Bộ Nội Vụ
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz
HC Wainwright Estimates Indivior's Q2 Earnings (NASDAQ:INDV) - MarketBeat
51,426 Shares in Indivior PLC $INDV Purchased by KLP Kapitalforvaltning AS - MarketBeat
Volume Recap: Is Indivior PLC forming higher highs and higher lows2025 Market Sentiment & Verified Entry Point Signals - baoquankhu1.vn
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Finviz
Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus - Yahoo Finance
Indivior stock price target raised to $48 from $35 at H.C. Wainwright - Investing.com Nigeria
INDV: Analyst Raises Price Target to $48.00, Maintains Buy Ratin - GuruFocus
Naloxone Market Is Going to Boom |EMERGENT, Indivior PLC, Akorn, Inc - openPR.com
Indivior PLC (INDV) Announces Full-Year 2026 Financial Guidance - Finviz
Indivior (NasdaqGS:INDV) Valuation Check After Strong Long Term Returns And Recent Price Consolidation - Yahoo Finance
Indivior PLCOrdinary Shares (NQ: INDV - FinancialContent
Indivior forecasts 11% SUBLOCADE growth, 35% EBITDA increase for 2026 By Investing.com - Investing.com Nigeria
Craig-Hallum raises Indivior stock price target to $50 on strong 2026 outlook - Investing.com Nigeria
Aug Closing: Why hedge funds are buying Indivior PLC stockWall Street Watch & Safe Entry Trade Signal Reports - moha.gov.vn
Can Indivior PLC stock double in next 5 years2025 Volume Leaders & Safe Entry Point Alerts - ulpravda.ru
Why Indivior PLC (2IVB) stock is a strong analyst pickWeekly Risk Summary & Safe Entry Point Identification - ulpravda.ru
Why retail investors pile into Indivior PLC stockJuly 2025 Momentum & Fast Moving Market Watchlists - ulpravda.ru
Is Indivior PLC stock a top pick in earnings season2025 Macro Impact & Fast Exit Strategy with Risk Control - ulpravda.ru
What margin trends mean for Indivior PLC stockWeekly Trade Report & Real-Time Chart Pattern Alerts - ulpravda.ru
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Finviz
Published on: 2026-01-08 20:56:58 - ulpravda.ru
How Indivior PLC stock performs during Fed tightening cycles2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
What analyst consensus says on Indivior PLC stock2025 AllTime Highs & Daily Technical Stock Forecast Reports - ulpravda.ru
Indivior Issues FY 2026 Financial Guidance - Nasdaq
Indivior shares rise after FY26 guidance tops consensus expectations By Investing.com - Investing.com Nigeria
Indivior PLC Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Indivior Expects Up to $1.20 Billion in 2026 Net Revenue - MarketScreener
(INDV) Indivior Expects 2026 Revenue Range $1.13B$1.2B, vs. FactSet Est of $1.19B - MarketScreener
Indivior Pharmaceuticals Inc (INDV) 財務データ
収益
当期純利益
現金流量
EPS
0.51%
9.76%
大文字化:
|
ボリューム (24 時間):